Algorithms and associated hardware that enhance the performance of existing cardiac devices (e.g., heart failure diagnosis, pacemaker ‘tuning’).
Aeglea BioTherapeutics is developing novel engineered human enzyme drug candidates that selectively target and inactivate amino acids required in tumorigenesis.
Preclinical-stage biopharmaceutical company developing small molecule therapeutics for cancer stem cells in the central nervous system for the treatment of glioblastoma multiforme (GBM) and other brain cancers.
Lumos Pharma is a biotechnology company dedicated to developing a treatment for Creatine Transporter Deficiency (CTD) patients and their families.
Developing treatments for niche, orphan drug indications for which there is no effective therapeutic option. First application: pleural disease.
Nanotechnology therapies that improve cancer treatment options for patients and physicians.
ATI and the Austin Community College District have partnered to launch startup business mentoring services within the ACC Bioscience Incubator (ABI).
The ABI wet-laboratory facility, opening in early 2017 at the ACC Highland Campus, will offer state-of-the-art biotechnology equipment, leasable wet-laboratories, conference areas and business mentoring services to assist entrepreneurs in transforming scientific discoveries into viable startup companies. The project is supported by local, state, and federal funding awards, including the Texas Emerging Technology Fund.